Residency · Residency · Critical Care

ICU-Acquired Weakness and Rehabilitation

Definition and Classification

ICU-Acquired Weakness (ICUAW)

ICU-acquired weakness is a clinically detected weakness developing in critically ill patients for which there is no plausible explanation other than the critical illness itself. It is diagnosed by the Medical Research Council (MRC) sum score, which evaluates 12 muscle groups bilaterally, each scored from 0 (no contraction) to 5 (normal strength), yielding a total score ranging from 0 to 60. A sum score below 48 defines ICUAW. The prevalence of ICUAW is alarmingly high, affecting 25 to 50 percent of patients ventilated for 7 days or longer and up to 80 percent of patients with septic shock. ICUAW is a major determinant of clinical trajectories in the ICU, contributing substantially to prolonged mechanical ventilation, increased ICU and hospital length of stay, long-term functional disability, and mortality.

Subtypes

Three overlapping subtypes of ICUAW are recognized, though in clinical practice they frequently coexist. Critical illness polyneuropathy (CIP) is an axonal sensorimotor polyneuropathy in which nerve conduction studies reveal reduced compound muscle action potential (CMAP) and sensory nerve action potential (SNAP) amplitudes with preserved conduction velocity, indicating axonal rather than demyelinating injury. The presence of sensory involvement distinguishes CIP from critical illness myopathy, though sensory testing is difficult to perform reliably in ICU patients.

Critical illness myopathy (CIM) is a primary myopathy characterized by preferential loss of myosin heavy chains. Electromyographic findings include short-duration, low-amplitude motor unit potentials with early recruitment patterns. Muscle biopsy, when performed, reveals type II fiber atrophy, myosin loss, and areas of necrosis. Direct muscle stimulation demonstrating reduced muscle membrane excitability is a key feature that distinguishes CIM from CIP, as the muscle itself is the site of dysfunction rather than the nerve.

Critical illness neuromyopathy (CINM) represents the overlap syndrome in which features of both CIP and CIM coexist. This is the most common clinical presentation, reflecting the reality that the pathophysiological mechanisms producing nerve and muscle injury in critical illness frequently operate in parallel.

Ventilator-Induced Diaphragm Dysfunction (VIDD)

The diaphragm is uniquely susceptible to the effects of critical illness and mechanical ventilation. Controlled mechanical ventilation produces diaphragm disuse atrophy within as few as 12 to 18 hours, mediated by activation of proteolytic pathways including the ubiquitin-proteasome system and autophagy. The concept of diaphragm-protective ventilation has emerged from the recognition that both overassistance, in which excessive ventilatory support completely unloads the diaphragm and produces atrophy, and underassistance, in which insufficient support causes excessive diaphragmatic loading and injury, are harmful. The goal is to maintain physiological diaphragmatic effort, as reflected by a diaphragm thickening fraction (TFdi) of 15 to 30 percent.

Pathophysiology

Risk Factors

Sepsis and systemic inflammation represent the strongest risk factor for ICUAW, as the inflammatory cascade directly injures both nerve and muscle tissue. Prolonged mechanical ventilation contributes through both immobilization and diaphragm-specific injury. Immobilization and bed rest accelerate muscle wasting through disuse atrophy. Corticosteroids and neuromuscular blocking agents have synergistic myotoxicity when used concurrently, producing a particularly severe form of acute myopathy. Prolonged neuromuscular blockade exceeding 48 hours is independently associated with ICUAW. Hyperglycemia impairs glucose utilization in muscle through insulin resistance. Multi-organ failure and increasing duration of ICU stay compound all of these risk factors.

Mechanisms

The pathophysiology of ICUAW involves parallel injury to both neural and muscular structures through interconnected mechanisms. In the nerve, microvascular dysfunction produces endoneurial edema and impaired nerve blood flow, leading to axonal degeneration. Ion channel dysfunction, specifically sodium channel inactivation, renders the muscle membrane inexcitable and prevents action potential propagation. Mitochondrial dysfunction impairs oxidative phosphorylation in both nerve and muscle tissue, reducing energy production at a time of increased metabolic demand.

In muscle, activation of the ubiquitin-proteasome pathway produces preferential degradation of myosin heavy chains, which are essential for force generation. Inflammatory mediators including TNF-alpha, IL-1, and IL-6 exert direct myotoxic effects and further activate proteolytic cascades. The rate of muscle loss in early critical illness can reach 3 to 4 percent of total muscle mass per day, a rate that far exceeds the approximately 0.5 percent per day seen with simple bed rest, underscoring the amplifying effect of the inflammatory milieu on disuse atrophy. Autophagy dysfunction, in which impaired cellular recycling prevents the removal of damaged organelles and proteins, may contribute to persistent weakness and delayed recovery.

<image>Pathophysiology diagram of ICU-acquired weakness showing parallel pathways for nerve and muscle injury. Left pathway (CIP): systemic inflammation → microvascular injury to vasa nervorum → endoneurial edema → sodium channel dysfunction → axonal degeneration. Show nerve cross-section with swollen axons and demyelination. Right pathway (CIM): systemic inflammation → direct myofiber injury → ubiquitin-proteasome activation → preferential myosin heavy chain degradation → type II fiber atrophy. Show muscle fiber cross-section with sarcomere disruption and myosin loss. Central contributing factors affecting both pathways: sepsis, hyperglycemia, corticosteroids, NMB agents, immobility, mitochondrial dysfunction. Bottom panel showing diaphragm-specific pathway: controlled ventilation → disuse → VIDD. Include risk factor icons and timeline of muscle loss (percentage per day graph over first 2 weeks).</image>

Diagnosis

Clinical Assessment

The MRC sum score is the primary bedside diagnostic tool, testing six bilateral muscle groups: shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and ankle dorsiflexion. Each muscle group is scored from 0 to 5, yielding a total score of 0 to 60, with ICUAW defined as a score below 48. This assessment requires patient cooperation, which means it cannot be performed in deeply sedated or comatose patients, creating a diagnostic gap during the period when ICUAW is likely developing. Additional limitations include subjectivity in scoring and a ceiling effect that may fail to detect mild weakness.

The pattern of weakness in ICUAW is characteristically symmetric and predominantly proximal, with relative sparing of the facial muscles. This latter feature is an important clinical distinction from Guillain-Barre syndrome, in which facial weakness is common. Deep tendon reflexes are diminished or absent in CIP but may be preserved or only mildly reduced in CIM. Sensory examination reveals decreased sensation in CIP but is normal in CIM, though reliable sensory testing in the ICU environment is challenging.

Electrophysiology

Electrophysiological studies provide definitive characterization of the underlying pathology. Nerve conduction studies demonstrate reduced CMAP amplitudes in both CIP and CIM, but reduced sensory nerve action potential (SNAP) amplitudes are seen only in CIP, providing a key distinction between the two entities. Electromyography reveals spontaneous activity such as fibrillations and positive sharp waves in denervated muscle (CIP) or short-duration myopathic motor unit potentials in CIM. Electrophysiological testing is most reliable after 7 to 10 days of ICU admission, as earlier testing may miss pathology that is still evolving. A peroneal nerve CMAP amplitude below 2 mV is a strong predictor of clinically significant ICUAW.

Ultrasound Assessment

Bedside ultrasonography has emerged as an increasingly valuable tool for diagnosing and monitoring ICUAW due to its non-invasive, repeatable, and objective nature. Muscle thickness measurements, most commonly of the rectus femoris and vastus intermedius (quadriceps), are obtained at two-thirds the distance from the anterior superior iliac spine to the superior border of the patella. A reduction in thickness exceeding 10 percent from baseline or a comparable decline in cross-sectional area indicates significant atrophy, with measurable changes detectable within 3 to 5 days of ICU admission. Increased muscle echogenicity on ultrasound indicates edema, fatty infiltration, or fibrosis, all markers of pathological change.

Diaphragm ultrasonography has become particularly important for assessing respiratory muscle function. Diaphragm thickness is measured at the zone of apposition, with normal values of 1.5 to 5 mm. Thickening fraction (TFdi), the proportional increase in diaphragm thickness from end-expiration to end-inspiration, provides a dynamic assessment of diaphragmatic contractility. A TFdi below 20 percent suggests excessive ventilator support or diaphragm dysfunction, while a TFdi above 30 to 40 percent may indicate injurious overloading. A diaphragm thickness below 2 mm indicates severe atrophy. Ultrasound is emerging as a standard ICU monitoring tool for neuromuscular assessment.

Muscle Biopsy

Muscle biopsy remains the gold standard for diagnosing CIM, revealing characteristic findings of myosin heavy chain loss, type II fiber atrophy, and necrosis. However, biopsy is rarely performed in clinical practice and is generally reserved for atypical presentations or research purposes. When indicated, bedside percutaneous biopsy of the quadriceps or tibialis anterior muscle can be performed at the bedside.

Prevention Strategies

Early Mobilization

Early mobilization is the strongest evidence-based intervention for the prevention of ICUAW and should be implemented as a standard of care in all ICU patients who meet safety criteria. Importantly, early mobilization has been demonstrated to be safe even in mechanically ventilated patients receiving vasopressors and continuous renal replacement therapy.

A progressive mobility protocol advances through sequential levels of activity: passive range of motion for sedated patients, active-assisted range of motion as sedation lightens, sitting at the edge of the bed, standing with assistance, and ultimately ambulating. Safety criteria for mobilization include hemodynamic stability (MAP greater than 65 mmHg on stable norepinephrine doses below 0.2 mcg/kg/min), adequate oxygenation (SpO2 above 90 percent), absence of active hemorrhage, no unstable fractures, and secure airway and vascular access devices.

The landmark trial by Schweickert et al. (2009) demonstrated that early physical and occupational therapy in mechanically ventilated patients improved functional independence at hospital discharge (59 percent versus 35 percent), reduced the duration of delirium (28 percent versus 41 percent of ICU days), and increased ventilator-free days. However, subsequent larger trials have tempered the initial enthusiasm. The TEAM trial (2022) found that early active mobilization compared to standard care did not improve 180-day functional outcomes, though it confirmed the safety of early mobilization. The interpretation of these seemingly discordant findings is that the quality and individualization of the mobility protocol matters more than simply implementing earlier activity, and that a one-size-fits-all approach may not capture the benefit seen in well-designed, resource-intensive programs.

Glycemic Control

Glycemic management has implications for ICUAW prevention. The Leuven trial demonstrated that tight glucose control (80-110 mg/dL) reduced the incidence of CIP and CIM. However, the NICE-SUGAR trial established that moderate glucose control targeting 144 to 180 mg/dL is preferred overall due to less hypoglycemia and no mortality difference compared to tight control. The current recommendation is to maintain glucose below 180 mg/dL while avoiding both hyperglycemia, which impairs muscle glucose utilization, and hypoglycemia, which carries its own risks of neuronal injury.

Minimizing Risk Factors

Targeted reduction of modifiable risk factors is an essential component of ICUAW prevention. Corticosteroid exposure should be limited to the lowest effective dose for the shortest possible duration. Neuromuscular blocking agents should be restricted to 24 to 48 hours when possible, though it is reassuring that the ROSE trial found no increased incidence of ICUAW with short-course neuromuscular blockade. Light sedation targets (RASS -2 to 0) reduce immobility and facilitate early mobilization. Comprehensive ABCDEF bundle compliance reduces delirium and promotes mobility, providing indirect but meaningful protection against ICUAW.

Nutritional Optimization

Adequate protein delivery at 1.2 to 2.0 g/kg/day is essential to counteract the massive catabolism of critical illness. Early enteral nutrition within 24 to 48 hours is recommended, though overfeeding must be avoided as it increases carbon dioxide production and may delay ventilator weaning. Supplemental nutritional strategies including beta-hydroxy-beta-methylbutyrate (HMB), leucine, and creatine have been investigated but evidence for their efficacy remains limited.

Neuromuscular Electrical Stimulation (NMES)

Neuromuscular electrical stimulation applies transcutaneous electrical impulses to peripheral muscles, with the quadriceps being the most commonly targeted group. NMES offers the unique advantage of providing muscle activation even in sedated or comatose patients who cannot participate in voluntary exercise. Some studies have demonstrated preservation of muscle mass and improvements in strength, while others have failed to show functional outcome improvements. Given its low risk profile and relative ease of implementation, NMES is a reasonable adjunctive intervention for high-risk patients.

<image>ICU rehabilitation protocol infographic showing progressive mobility levels as ascending steps from left to right. Level 1 (supine, sedated): passive range of motion exercises, NMES to quadriceps and anterior tibialis, in-bed cycling, HOB elevation. Level 2 (lightening sedation): active-assisted exercises, seated in bed, dangling legs at bedside. Level 3 (awake, cooperative): sitting in chair, active resistance exercises, standing with assistance, tilt table if needed. Level 4 (stable, minimal support): walking with assistance, in-room cycling, functional task training. Level 5 (progressing): independent ambulation, stair climbing, discharge planning. Each level includes: safety criteria checklist (hemodynamic, respiratory, neurological thresholds), staffing requirements, equipment needed, and approximate timeline in ICU days. Include contraindications panel and team members involved (PT, OT, RT, nursing, physician).</image>

Long-Term Outcomes

Physical Recovery

The long-term physical consequences of ICUAW and critical illness are substantial and persistent. The landmark studies by Herridge et al. in ARDS survivors demonstrated significant functional impairment persisting at 5 years after ICU discharge. Six-minute walk distance remained reduced to approximately 60 percent of predicted at 1 year and only recovered to about 70 percent of predicted at 5 years. Muscle weakness persists in 35 percent of ICU survivors at 1 year, and only 49 percent of survivors return to work within the first year following ICU discharge. Functional recovery continues for 12 to 24 months but rarely reaches the pre-illness baseline, highlighting the need for sustained rehabilitation efforts well beyond hospital discharge.

Post-Intensive Care Syndrome (PICS)

Post-intensive care syndrome is a composite of physical, cognitive, and mental health impairments that persist after critical illness and profoundly affects quality of life. The physical domain encompasses weakness, fatigue, reduced exercise tolerance, and sexual dysfunction. The cognitive domain, affecting 25 to 30 percent of patients at 1 year, includes memory deficits, executive dysfunction, and attention difficulties that may mimic early dementia. The mental health domain includes post-traumatic stress disorder (20 to 25 percent), depression (30 to 40 percent), and anxiety (40 to 50 percent). PICS-Family recognizes the substantial burden borne by caregivers and family members of ICU survivors, who themselves experience high rates of depression, anxiety, and complicated grief.

ICU Follow-Up

Structured post-ICU follow-up is increasingly recognized as an essential component of critical care medicine. Post-ICU clinics provide multidisciplinary assessment incorporating medicine, physical therapy, occupational therapy, neuropsychology, and social work. Screening for PTSD, depression, and cognitive impairment should be performed systematically. Medication reconciliation is essential to de-prescribe ICU-initiated medications that are no longer needed, as many patients are discharged on unnecessary sedatives, analgesics, or antipsychotics. Pulmonary function testing commonly reveals a restrictive pattern with reduced diffusion capacity. Rehabilitation referrals for inpatient rehabilitation, home-based programs, or pulmonary rehabilitation should be tailored to individual deficits and functional goals.

Special Considerations

Prolonged Mechanical Ventilation and Weaning Failure

ICUAW is the most common cause of weaning failure in patients who have been mechanically ventilated for more than 7 days. Diaphragm ultrasound provides essential bedside assessment, with a TFdi below 20 percent predicting extubation failure. Inspiratory muscle training using threshold inspiratory muscle training devices, performed for 5 to 15 minutes twice daily with progressive loading, can improve maximal inspiratory pressure and reduce weaning duration according to meta-analyses. Tracheostomy facilitates rehabilitation in patients requiring prolonged mechanical ventilation by reducing sedation requirements, improving mobility, enabling oral intake, and allowing speech with a speaking valve.

Steroid Myopathy

Acute steroid myopathy is a distinct entity occurring with high-dose intravenous corticosteroid administration, particularly when combined with neuromuscular blocking agents. It is characterized by severe proximal weakness, elevated creatine kinase, and muscle biopsy showing type II fiber atrophy with vacuolar changes. This is distinct from chronic steroid myopathy, which develops gradually over weeks to months and produces normal CK levels. Management involves discontinuation or reduction of corticosteroids and supportive rehabilitation.

Critical Illness-Associated Entrapment Neuropathies

Peripheral nerve injuries from positioning and compression are a preventable complication of ICU care. The most common entrapment neuropathies include ulnar neuropathy at the elbow and peroneal neuropathy at the fibular head. Prevention requires meticulous attention to positioning, with pressure point padding and limb repositioning every 2 hours. During prone positioning, particular awareness of brachial plexopathy risk from arm positioning is essential.

Key Clinical Pearls

• ICUAW affects 25-50% of patients ventilated >7 days and is a major determinant of long-term functional outcomes
• MRC sum score <48/60 defines ICUAW — requires patient cooperation, so cannot be assessed in deeply sedated patients
• Diaphragm ultrasound (thickening fraction and thickness) is the most practical bedside tool for assessing both limb and respiratory muscle dysfunction
• Early mobilization is safe and the best-studied ICUAW prevention strategy — implement progressive mobility protocols for all ICU patients
• The combination of corticosteroids + NMB has synergistic myotoxicity — minimize concurrent use when possible
• PICS (physical, cognitive, mental health impairments) persists for years after ICU discharge — plan for multidisciplinary follow-up
• Inspiratory muscle training may reduce weaning duration in patients with prolonged MV and diaphragm weakness
• Muscle wasting begins within hours of ICU admission and can reach 3-4% of total muscle mass per day — prevention must start immediately

References

1. Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. Crit Care. 2015;19(1):274.
2. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009;373(9678):1874-1882.
3. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364(14):1293-1304.
4. Goligher EC, Dres M, Fan E, et al. Mechanical ventilation-induced diaphragm atrophy strongly impacts clinical outcomes. Am J Respir Crit Care Med. 2018;197(2):204-213.
5. TEAM Study Investigators. Early active mobilization during mechanical ventilation in the ICU. N Engl J Med. 2022;387(19):1747-1758.

Read this lecture as Markdown